Article: What’s a Better Way To Finance Drug Dev – Open Source or Patent Financing?

Drugs, Open Health, Open Source

What’s a Better Way To Finance Drug Dev – Open Source or Patent Financing?

It is often said that intellectuals have a hard time dealing with new ideas. Unfortunately, for purposes of public debate, open-source government funding of drug development is a new idea, and people in policy positions seem to be having a very hard time understanding it. So, I will try to write this post in a way that even a policy wonk can figure it out.

The basic idea of government-funded research should not be hard to grasp since the government already funds a large share of biomedical research. The National Institutes of Health gets over $40 billion a year in federal funding, with the Biomedical Advanced Research and Development Agency (BARDA) and other government agencies getting several billion more.

Read Full Article

Article: Open-Source Versus Patent Monopoly Financing of Drug Development

Cures, Open Governance, Open Health, Standards

Open-Source Versus Patent Monopoly Financing of Drug Development

It is often said that intellectuals have a hard time dealing with new ideas. Unfortunately, for purposes of public debate, open-source government funding of drug development is a new idea, and people in policy positions seem to be having a very hard time understanding it. So, I will try to write this post in a way that even a policy wonk can figure it out.

The basic idea of government-funded research should not be hard to grasp since the government already funds a large share of biomedical research.

Read Full Article

Article: Scientists reverse-engineered the Moderna vaccine, post RNA sequence online for free

Cures, Open Health

Scientists reverse-engineered the Moderna vaccine, post RNA sequence online for free

Researchers at Stanford University sequenced the RNA components of the initial Moderna and Pfizer-BioNTech COVID-19 vaccines, then posted the two-page-long sequences in their entirety on GitHub.

One of the few good things out of this pandemic was that urgency of the matter fast-tracked RNA-based vaccines, which could end up being far cheaper and quicker to make than traditional vaccines.

Read Full Article